David Frankel

David Frankel is a managing partner at Founder Collective, and the angel activity catalogued here reflects his role as a connector between Israeli founders and the US venture ecosystem. Based in Tel Aviv, he writes personal checks into early-stage digital health companies, often functioning as the first US-savvy investor on a cap table that is otherwise local. Founders who want someone who has watched hundreds of seed-stage companies translate into real US businesses tend to find the engagement useful.

The thesis at the angel level is digital health, with an emphasis on Israeli founders building products intended for the US market. The questions he asks are usually about distribution, regulatory readiness, and the choice of which US healthcare buyer the company is actually serving. AI focus is real, but the emphasis is on whether the product solves a clinical or workflow problem that a US payer, provider, or employer will pay for. Founders without a clear US thesis tend to be a poor fit.

Checks fall in the two hundred and fifty thousand to one million dollar range, deployed at pre-seed and seed. He participates rather than leads, and the leverage on the cap table is the bridge function: introductions, market intelligence, and a credible voice when the next investor is a US fund. Geography is the Israel-US corridor, with the Tel Aviv base creating proximity to local founders and the Founder Collective relationship providing visibility into the US market.

Frankel’s day job is at Founder Collective, and the angel checks are personal capital, distinct from the firm’s institutional fund. Founders should treat the angel relationship as exactly what it is rather than as an implicit pre-commitment from the firm.

The approach is operationally focused on the cross-border specifics that often go wrong. He is most useful on go-to-market sequencing into US healthcare buyers, the choice of US co-investors at the next round, the credibility-building work that Israeli founders need to do before US institutional funds engage, and the unglamorous mechanics of running a transatlantic company. Process is light and conversational, with diligence resolved through working sessions rather than formal review. Follow-on is not promised and depends on his own conviction at the next round. For Israeli digital health founders building toward a US market and looking for an angel who can credibly bridge the two ecosystems, the fit is unusually direct.